Biobetters

The term biobetter refers to a recombinant protein drug that is in the same class as an existing biopharmaceutical but is not identical; it is improved over the original. Biobetters build on the success of existing, approved biologics but are considered less of a commercial risk than developing a brand new class of biologic. Biobetters are not entirely new drugs and they aren't generic versions of drugs, either. While many consider biosimilars to be generic versions of biotech drugs, it isn't possible to create a generic biologic drug. That's because biopharmaceuticals are produced in living organisms - such as animals or bacteria - and cannot be copied exactly.

    Related Conference of Biobetters

    July 27-28, 2026

    19th World Drug Delivery Summit

    Paris, France
    July 27-28, 2026

    39th World Congress on Pharmacology

    Rome, Italy
    September 14-15, 2026

    6th International Conference on Pharmaceutical Chemistry

    Paris, France
    September 24-25, 2026

    6th World Congress on Rare Diseases & Orphan Drugs

    Paris, France
    November 26-27, 2026

    5th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    November 26-27, 2026

    5th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    December 14-15, 2026

    5th Global Summit on Pharmaceutical Research

    Paris, France
    January 26-27, 2027

    22nd Annual Meet on Pharmaceutical Sciences

    Paris, France
    April 27-28, 2027

    10th European Biopharma Congress

    Paris, France

    Biobetters Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in